10.1021/pr5011718.s003
Yunli Hu
Yunli
Hu
Anoop Mayampurath
Anoop
Mayampurath
Saira Khan
Saira
Khan
Joanna
K. Cohen
Joanna
K.
Cohen
Yehia Mechref
Yehia
Mechref
Samuel L. Volchenboum
Samuel L.
Volchenboum
N‑Linked Glycan Profiling
in Neuroblastoma
Cell Lines
American Chemical Society
2015
bioinformatics analysis
16 glycans
marker candidates
sugar abundance
protein residues
glycosylation
NLF
protein modification
neuroblastoma risk diagnosis
sialylated glycan structures
Neuroblastoma Cell LinesAlthough MYCN amplification
results offer clues
glycomic markers
monosaccharide count
SY 5Y samples
nonsialylated glycans
proteomic studies
precancerous conditions
2015-05-01 00:00:00
Journal contribution
https://acs.figshare.com/articles/journal_contribution/N_Linked_Glycan_Profiling_in_Neuroblastoma_Cell_Lines/2171125
Although <i>MYCN</i> amplification
has been associated
with aggressive neuroblastoma, the molecular mechanisms that differentiate
low-risk, <i>MYCN</i>-nonamplified neuroblastoma from high-risk, <i>MYCN</i>-amplified disease are largely unknown. Genomic and
proteomic studies have been limited in discerning differences in signaling
pathways that account for this heterogeneity. N-Linked glycosylation
is a common protein modification resulting from the attachment of
sugars to protein residues and is important in cell signaling and
immune response. Aberrant N-linked glycosylation has been routinely
linked to various cancers. In particular, glycomic markers have often
proven to be useful in distinguishing cancers from precancerous conditions.
Here, we perform a systematic comparison of N-linked glycomic variation
between <i>MYCN</i>-nonamplified SY5Y and <i>MYCN</i>-amplified NLF cell lines with the aim of identifying changes in
sugar abundance linked to high-risk neuroblastoma. Through a combination
of liquid chromatography–mass spectrometry and bioinformatics
analysis, we identified 16 glycans that show a statistically significant
change in abundance between NLF and SY5Y samples. Closer examination
revealed the preference for larger (in terms of total monosaccharide
count) and more sialylated glycan structures in the <i>MYCN</i>-amplified samples in comparison to smaller, nonsialylated glycans
that are more dominant in the <i>MYCN</i>-nonamplified samples.
These results offer clues for deriving marker candidates for accurate
neuroblastoma risk diagnosis.